PASSconviction 3published 2026-09-09

NGVC — Natural Grocers by Vitamin Cottage, Inc. · 2026-09-09 · Verdict: PASS · Conviction 3

Price $27.16 (screen row, 2026-09-09 build) · Mkt cap $626M · EV $656M (corrected) · EV/normalised EBIT 10.7x · FCF yield 3.6% · Net debt $29.8M · ADV $3.9M Sources read: 10-K filed 2025-12-11 for FY ended 2025-09-30 (Items 1, 1A, 7), 10-Q filed 2026-08-06 for Q3 FY26 ended 2026-06-30, DEF 14A 2026-01-22, 8-Ks 2026-05-07 and 2026-08-06, Form 4s (12m). No earnings call transcript or prepared remarks exist in the bundle; the company files no such exhibit, so all management quotes below come from the Q3 press release (8-K 2026-08-06, EX-99.1).

Desk stats - Revenue trend: FY2025 net sales $1,330.8M, up 7.2%, on daily average comparable store sales of +7.3%, itself 4.6% transaction count and 2.6% ticket (10-K FY25, Item 7). Q3 FY26 net sales $334.7M, up 1.8%, on comps of +1.2% made of ticket +3.1% and transaction count -1.8% (10-Q Q3 FY26, Item 2). The driver has flipped from traffic to price. - Normalised after-tax operating profit: LTM GAAP operating income $63.3M (FY25 $62.0M less 9M FY25 $46.5M plus 9M FY26 $47.7M). Adjustments: subtract the $2.0M business interruption insurance recovery gain booked in Q3 FY26 administrative expenses for the June-July 2025 UNFI cyber incident (10-Q, Item 2); add back $0.045M of long-lived asset impairment and store closing costs (10-Q EBITDA reconciliation). Normalised operating income $61.3M; taxed at 25%, $46.0M against a GAAP-basis $47.4M. - EV / normalised after-tax profit: 14.3x on the corrected EV of $655.7M ($626M cap + $45.8M finance leases + $1.5M Co-PACE - $17.5M cash, all per the 8-K 2026-08-06 balance sheet). On the screen's EV of $609.9M it is 13.3x. - Leverage: net debt $29.8M / normalised EBITDA $93.8M = 0.32x. Nothing drawn on the $70.0M revolver, in compliance with all covenants (10-Q). Separately, $275.5M of operating lease obligations sit outside that figure; total lease obligations of $321.2M are 51% of the market cap. - Is the growth sustainable? Organic and cash-backed but decelerating hard and guided down twice this year: the FY26 comp guide went 1.5-4.0% to 1.5-2.5% (8-K 2026-05-07) to 1.5-2.0% (8-K 2026-08-06), with the EPS top end cut to $2.11. - What the screen got wrong: it read only us-gaap:LongTermDebtNoncurrent of $1.4M and so called this net cash of $16.1M. It missed $45.8M of finance lease obligations, which carry fixed payments and interest expense. Real net debt is $29.8M and true EV is 7.5% higher than screened. The correction runs against the company, not for it.

1. What the business actually does

Natural Grocers is a family-run specialty grocer selling only natural and organic food, body care and dietary supplements, from 174 stores in 22 states as of the August 2026 release. Stores are deliberately small, about 11,000 selling square feet carrying roughly 20,000 SKUs, of which about 6,500 are supplements occupying a quarter of the floor (10-K, Item 1). The differentiators are hard product standards (no artificial preservatives or sweeteners, only USDA certified organic produce, no antibiotics or hormones in meat), an "Always Affordable Price" posture, and a Nutritional Health Coach in every store. The second generation of the Isely family took control in 1998 and grew the chain from 11 stores to 169 by FY2025. Supply is concentrated: UNFI is about 69% of total purchases under an agreement running to September 3, 2028, and the top 20 suppliers are 84% (10-K, Item 1).

2. Why it is mispriced — the edge case

There is none, and that decides the verdict. No spin, no index event, no restatement, no forced seller. The stock is 32% off its 52-week high, but the proxy's own pay-versus-performance table shows a $100 investment growing to $419.40 over the three years to FY2025 (DEF 14A 2026-01-22). This quadrupled and then gave back a third, and it has already recovered 8.3% over six months on $3.9M of daily volume. The -25.6% twelve-month momentum is a multiple normalising after an inflation-and-supplements boom, not a dislocation. The Isely family group owns 57.9% and votes as a bloc under a Stockholders Agreement, which keeps the float small but is a permanent feature rather than a temporary distortion, and it removes any takeover or activist route (DEF 14A). Insiders bought nothing in twelve months across 25 Form 4 rows; the only open-market transaction was Charity Isely selling 3,000 shares at $29.04 on 2026-05-29.

3. Unit economics and growth

The business is genuinely good. Gross margin rose from 28.7% to 29.4% to 29.9% over FY2023-FY2025 on product margin and occupancy leverage, and operating margin from 2.8% to 3.8% to 4.7% (10-K, Item 7). Normalised ROIC on $269M of invested capital is about 17%, with no goodwill of consequence ($5.2M).

The trend has turned. Comps ran +7.3% in FY25 but only +1.1% for the first nine months of FY26, with Q2 at +0.5% and Q3 at +1.2% (10-Q). All of it is ticket: transaction count fell 1.1% in Q2 and 1.8% in Q3. Q3 gross margin fell to 29.3% from 29.9% on unfavourable mix, higher shrink and freight, though the company fairly notes the prior-year UNFI shortage distorts that comparison. Strip the $2.0M insurance gain out of Q3 operating income and clean operating profit was $13.0M against $15.6M, down 16.6%, while reported operating income fell only 3.8%.

Unit growth is the one thing improving: six stores opened in the first ten months of FY26 against two in all of FY25, taking twelve-month unit growth to 1.8% from 0.6%. But management targets 4-5% annual unit growth "for the foreseeable future" while compounding store count at 1.2% over five fiscal years (10-K, Item 7), and it trimmed the FY26 plan from 6-8 stores to 6-7 in August.

4. Balance sheet and capital allocation

Clean: $17.5M cash, nothing drawn on a $70.0M revolver maturing November 16, 2028, $1.5M of Co-PACE financing at 5.9% assumed on a future headquarters building, and $45.8M of finance leases. The credit agreement caps buybacks plus dividends at $15.0M a year, the binding constraint on capital returns. The dividend rose from $0.12 to $0.15 quarterly in November 2025, about $13.8M annualised, a 2.2% yield that nearly consumes that cap. The buyback is effectively dead: $8.1M remains authorised, nothing was repurchased in FY25 or Q3 FY26, and the board simply extended the program to May 31, 2028. Share count rose 0.4% to 23.0M. FY26 capex is guided at $45-50M against $32.5M of LTM depreciation, so growth is consuming the cash: LTM free cash flow was $22.4M, a 3.6% yield. The four Isely executives take salary only, no equity and in two cases no bonus, on the stated logic that their ownership is alignment enough; related-party store leases with family entities cost $1.3M in FY25 (DEF 14A).

5. Management: what they said vs what they did

Kemper Isely framed Q3 as comps "accelerating to 1.2% from 0.5% in the second quarter" (8-K 2026-08-06). True, and the two-year stack of 8.6% is respectable. But the same release cut both the comp guide and the new-store plan, and the acceleration he cites is entirely ticket against falling traffic, which the release discloses a paragraph later and the quote does not mention. Against last year's promises: FY26 comps were guided at 1.5-4.0% and will land at 1.5-2.0%, and the 4-5% unit growth target has not been met in any of five years.

6. Valuation

At $27.16 you pay 14.3x normalised after-tax operating profit, 10.7x normalised EBIT, 7.0x normalised EBITDA and 13.0x the $2.07-$2.11 FY26 EPS guide.

Probability-weighted $28.95, about 7% above price. Reverse DCF: at a 9% discount rate the $655.7M enterprise value against $46.0M of normalised after-tax operating profit implies about 2.0% perpetual growth, roughly the comp guide the company just issued, so the price is neither demanding nor generous. That 2.0% also assumes maintenance capex equals depreciation; on the guided $45-50M of capex, steady free cash flow is nearer $31M, a 4.7% unlevered yield.

7. Catalysts and timeline

Q4 FY26 results and the first FY2027 guidance, expected early December 2026, which will show whether the six-to-seven new store class restores traffic. The UNFI agreement renewal, September 3, 2028, is the one structural event.

8. Risks and pre-registered kill criteria

Observable tests that would make this PASS wrong, or confirm it: 1. Traffic. Daily average transaction count positive in both Q4 FY26 and Q1 FY27 would say the -1.8% was a compare rather than a trend, and this becomes interesting. 2. FY27 guidance. Comps guided below 2.0%, or EPS below $2.11, in the December release confirms the PASS; comps above 3.0% with 4%-plus unit growth flips it. 3. Gross margin below 29.0% for two consecutive quarters breaks the margin-expansion record that justifies the multiple. 4. Capex above $50M in FY27 with free cash flow still below $30M shows the unit growth is not paying for itself.

Company-specific risks: 69% supplier concentration in UNFI, which already caused a shortage in June-July 2025; dietary supplement regulation and DSHEA class-action exposure; and controlled-company status, which exempts the board from NYSE independence requirements and means no outside party can force change (10-K, Item 1A).

9. Verdict and one-paragraph summary

PASS, conviction 3. Natural Grocers is a genuinely good small business, a 17% ROIC specialty grocer with no net leverage, five straight years of gross margin expansion and a family that owns 58% and pays itself in salary rather than options, but nothing about it is mispriced. The screen's "net cash $16M" is wrong because it read only the $1.4M Co-PACE line and missed $45.8M of finance lease obligations, so real enterprise value is $656M and the real multiple is 14.3x normalised after-tax operating profit, not 13.1x. That price implies about 2% perpetual growth, which is what the company just guided to after cutting its comp outlook twice in one year, from 1.5-4.0% to 1.5-2.0%. The composition of growth has deteriorated in a way the headline hides: June-quarter comps of +1.2% are ticket of +3.1% against transaction count of -1.8%, and once you remove the $2.0M insurance recovery the company itself excludes from Adjusted EBITDA, clean quarterly operating profit fell 16.6% rather than the reported 3.8%. There is no forced seller, no artifact and no catalyst; the stock quadrupled over the three years to FY2025, gave back a third, and has already bounced 8% in six months while insiders bought nothing and sold at $29.04. Probability-weighted value of $28.95 is 7% above price, which does not pay for a retailer whose traffic is falling and whose $45-50M capex program consumes two thirds of its operating profit. Revisit in December if FY27 is guided to comps above 3% with transaction count positive.

Research for discussion, not investment advice. Positions and sizing are the reader's decision.

Source markdown: 2026-09-09_NGVC.md · how these notes are built · every verdict tracked since publication.

Research and education only. Nothing here is investment advice or a recommendation to buy or sell any security. No price targets are recommendations; positions and sizing are the reader's decision. Past performance does not predict future results.